Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy - PubMed (original) (raw)
. 1989 Feb 1;81(3):216-20.
doi: 10.1093/jnci/81.3.216.
Affiliations
- PMID: 2911084
- DOI: 10.1093/jnci/81.3.216
Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy
M C Bibby et al. J Natl Cancer Inst. 1989.
Abstract
Flavone acetic acid (FAA) is active against normally refractory murine sc tumors. Clinical studies are disappointing despite achievement of plasma profiles associated with the antitumor murine activity in man. To clarify the mechanism of action, we have followed histologic changes, tumor blood volume, and drug concentrations in a well-differentiated, slow-growing cystic adenocarcinoma in mice. FAA causes massive tumor necrosis beginning 2 hours after treatment. Tumor plasma volumes are reduced by 2 hours after treatment and tumor blood vessels are shutdown, which suggests that tumor vasculature plays a role in the dramatic response of sc tumors in pure-strain male NMRI mice.
Similar articles
- Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.
Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Zwi LJ, et al. J Natl Cancer Inst. 1989 Jul 5;81(13):1005-13. doi: 10.1093/jnci/81.13.1005. J Natl Cancer Inst. 1989. PMID: 2733044 - Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action.
Hill S, Williams KB, Denekamp J. Hill S, et al. Eur J Cancer Clin Oncol. 1989 Oct;25(10):1419-24. doi: 10.1016/0277-5379(89)90099-0. Eur J Cancer Clin Oncol. 1989. PMID: 2591434 - Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.
O'Dwyer PJ, Shoemaker D, Zaharko DS, Grieshaber C, Plowman J, Corbett T, Valeriote F, King SA, Cradock J, Hoth DF, et al. O'Dwyer PJ, et al. Cancer Chemother Pharmacol. 1987;19(1):6-10. doi: 10.1007/BF00296246. Cancer Chemother Pharmacol. 1987. PMID: 3545524 Review. - Flavone acetic acid--from laboratory to clinic and back.
Bibby MC, Double JA. Bibby MC, et al. Anticancer Drugs. 1993 Feb;4(1):3-17. doi: 10.1097/00001813-199302000-00001. Anticancer Drugs. 1993. PMID: 8457711 Review.
Cited by
- Identification and induction of cytochrome P450s involved in the metabolism of flavone-8-acetic acid in mice.
Pham MH, Rhinn H, Auzeil N, Regazzetti A, Harami DE, Scherman D, Chabot GG. Pham MH, et al. Drug Metab Lett. 2011 Apr;5(2):73-84. doi: 10.2174/187231211795305221. Drug Metab Lett. 2011. PMID: 21457135 Free PMC article. - Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.
Newell DR, Searle KM, Westwood NB, Burtles SS; Cancer Research UK Phase I/II Clinical Trials Committee. Newell DR, et al. Br J Cancer. 2003 Aug 4;89(3):437-54. doi: 10.1038/sj.bjc.6601106. Br J Cancer. 2003. PMID: 12888809 Free PMC article. No abstract available. - 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Zhou S, Kestell P, Baguley BC, Paxton JW. Zhou S, et al. Invest New Drugs. 2002 Aug;20(3):281-95. doi: 10.1023/a:1016215015530. Invest New Drugs. 2002. PMID: 12201491 Review. - A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.
Hori K, Saito S, Kubota K. Hori K, et al. Br J Cancer. 2002 May 20;86(10):1604-14. doi: 10.1038/sj.bjc.6600296. Br J Cancer. 2002. PMID: 12085211 Free PMC article. - The biology of the combretastatins as tumour vascular targeting agents.
Tozer GM, Kanthou C, Parkins CS, Hill SA. Tozer GM, et al. Int J Exp Pathol. 2002 Feb;83(1):21-38. doi: 10.1046/j.1365-2613.2002.00211.x. Int J Exp Pathol. 2002. PMID: 12059907 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous